Evidence map›Paper›PMID 40841853›Full record

Observational studyRenal failure2025

Dose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study.

Takahiro Kato, Yusuke Nakano, Noriko Yasukawa, Masafumi Oonishi, Yukihiro Hamada

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takahiro KatoDepartment of Pharmacy, Kochi Medical School Hospital, Kochi, Japan.
Yusuke NakanoDepartment of Cardiology, Aichi Medical University, Nagakute, Aichi, Japan.
Noriko YasukawaDepartment of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
Masafumi OonishiDepartment of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
Yukihiro HamadaDepartment of Pharmacy, Kochi Medical School Hospital, Kochi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the dose-dependent renoprotective effects of sacubitril/valsartan in heart failure patients. This retrospective observational study included patients with heart failure (Stage B or higher, B-type natriuretic peptide (BNP) >100 pg/mL or N-terminal proBNP >300 pg/mL) who initiated sacubitril/valsartan (SV) treatment. Patients were classified by final SV daily dose (50, 100, 200, or 400 mg) at 18 months. Factors associated with eGFR changes were identified using multiple regression analysis. A total of 157 patients (mean age 74.8-77.9 years, 64.3% male) were stratified by daily SV dosage groups (50 mg,

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsHeart FailureTetrazolesValsartanAgedBiphenyl CompoundsDose-Response Relationship, DrugDrug CombinationsFemaleGlomerular Filtration RateHumansMaleNatriuretic Peptide, BrainPeptide FragmentsRetrospective StudiesAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)sacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanangiotensin receptor neprilysin inhibitorcardiorenal syndromeHeart failureproteinuriarenal protectionsacubitril/valsartan

Identifiers

PMID40841853
PMCPMC12372510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.